

Marco Filetti

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4662335/publications.pdf>

Version: 2024-02-01

25
papers

1,314
citations

840776

11
h-index

794594

19
g-index

27
all docs

27
docs citations

27
times ranked

1853
citing authors

#	ARTICLE	IF	CITATIONS
1	A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable. , 2019, 7, 57.		275
2	Clinical Outcomes of Patients with Advanced Cancer and Pre-Existing Autoimmune Diseases Treated with Anti-Programmed Death-1 Immunotherapy: A Real-World Transverse Study. Oncologist, 2019, 24, e327-e337.	3.7	131
3	Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practice. , 2020, 8, e001361.		126
4	Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients. Clinical Lung Cancer, 2019, 20, 237-247.e1.	2.6	118
5	Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events. European Journal of Cancer, 2020, 128, 17-26.	2.8	85
6	Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel prognostic index. European Journal of Cancer, 2021, 142, 18-28.	2.8	81
7	Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy. , 2021, 9, e002421.		80
8	Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of $\geq 50\%$. Cancer Immunology, Immunotherapy, 2020, 69, 2209-2221.	4.2	60
9	Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression $\geq 50\%$: a multicenter study with external validation. , 2020, 8, e001403.		57
10	Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression $\geq 50\%$ and Their Relationship With Clinical Outcomes. Clinical Lung Cancer, 2020, 21, 498-508.e2.	2.6	50
11	Late immune-related adverse events in long-term responders to PD-1/PD-L1 checkpoint inhibitors: A multicentre study. European Journal of Cancer, 2020, 134, 19-28.	2.8	45
12	Smoking status during first-line immunotherapy and chemotherapy in <scp>NSCLC</scp> patients: A caseâ€“control matched analysis from a large multicenter study. Thoracic Cancer, 2021, 12, 880-889.	1.9	30
13	CT based radiomic approach on first line pembrolizumab in lung cancer. Scientific Reports, 2021, 11, 6633.	3.3	25
14	Predictive ability of a drug-based score in patients with advanced nonâ€“small-cell lung cancer receiving first-line immunotherapy. European Journal of Cancer, 2021, 150, 224-231.	2.8	24
15	Post-progression outcomes of NSCLC patients with PD-L1 expression $\geq 50\%$ receiving first-line single-agent pembrolizumab in a large multicentre real-world study. European Journal of Cancer, 2021, 148, 24-35.	2.8	19
16	INfluenza Vaccine Indication During therapy with Immune checkpoint inhibitors: a multicenter prospective observational study (INVIDia-2). , 2021, 9, e002619.		17
17	Statins and immunotherapy: Togetherness makes strength The potential effect of statins on immunotherapy for <scp>NSCLC</scp>. Cancer Reports, 2021, 4, e1368.	1.4	14
18	PD-1/PD-L1 checkpoint inhibitors during late stages of life: an ad-hoc analysis from a large multicenter cohort. Journal of Translational Medicine, 2021, 19, 270.	4.4	14

#	ARTICLE	IF	CITATIONS
19	Efficacy of immunotherapy in lung cancer with co-occurring mutations in NOTCH and homologous repair genes. , 2020, 8, e000946.		13
20	Impact of tumor site on the prognosis of small bowel adenocarcinoma. Tumori, 2019, 105, 524-528.	1.1	12
21	Palliative- and non-palliative indications for glucocorticoids use in course of immune-checkpoint inhibition. Current evidence and future perspectives. Critical Reviews in Oncology/Hematology, 2021, 157, 103176.	4.4	11
22	Clinical outcomes of NSCLC patients experiencing early immune-related adverse events to PD-1/PD-L1 checkpoint inhibitors leading to treatment discontinuation. Cancer Immunology, Immunotherapy, 2022, 71, 865-874.	4.2	11
23	Evaluating the role of FAMiLy history of cancer and diagnosis of multiple neoplasms in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: the multicenter FAMi-L1 study. Oncoimmunology, 2020, 9, 1710389.	4.6	9
24	Patientsâ€™ Satisfaction with Breakthrough Cancer Pain Therapy: A Secondary Analysis of IOPS-MS Study. Cancer Management and Research, 2022, Volume 14, 1237-1245.	1.9	4
25	Exploring the molecular insights of concurrent composite mucoepidermoid carcinoma and papillary thyroid carcinoma. Endocrine, 2020, 68, 230-232.	2.3	3